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Abstract
Background: Postherpetic neuralgia (PHN) is by far the most common complication of herpes
zoster (HZ) and one of the most intractable pain disorders. Since PHN is seen most often in the
elderly, the number of patients with this disorder is expected to increase in our ageing society.
PHN may last for months to years and has a high impact on the quality of life. The results of PHN
treatment are rather disappointing. Epidural injection of local anaesthetics and steroids in the acute
phase of HZ is a promising therapy for the prevention of PHN. Since randomised trials on the
effectiveness of this intervention are lacking, the PINE (Prevention by epidural Injection of
postherpetic Neuralgia in the Elderly) study was set up. The PINE study compares the effectiveness
and cost-effectiveness of a single epidural injection of local anaesthetics and steroids during the
acute phase of HZ with that of care-as-usual (i.e. antivirals and analgesics) in preventing PHN in
elderly patients.
Methods / design: The PINE study is an open, multicenter clinical trial in which 550 elderly (age
≥ 50 yr.) patients who consult their general practitioner in the acute phase of HZ (rash < 7 days)
are randomised to one of the treatment groups. The primary clinical endpoint is the presence of
HZ-related pain one month after the onset of the rash. Secondary endpoints include duration and
severity of pain, re-interventions aiming to treat the existing pain, side effects, quality of life, and
cost-effectiveness.
Conclusion: The PINE study is aimed to quantify the (cost-) effectiveness of a single epidural
injection during the acute phase of HZ on the prevention of PHN.
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Background
Herpes zoster (HZ) or shingles is a common disease, with
a reported incidence varying from 2.2 to 3.4/1000 per-
sons/year [1-4]. This incidence increases with age, rising
from 2.4/1000 persons/year in younger subjects to 6.9/
1000 persons/year in individuals older than 55 years of
age [2,4,5]. The symptoms of HZ include a painful, vesic-
ular rash with erythema.
It is a self-limiting disease for most patients, with healing
of the skin and resolution of the pain generally occurring
within three to four weeks. The most frequent complica-
tion of HZ is persistent pain that may last for several
months or years, also called postherpetic neuralgia
(PHN). PHN is commonly defined as the presence of HZ-
related pain one month or more after the onset of the rash
[5-7], whereas some use the threshold of three months
[8,9]. This chronic pain has a potentially high impact on
the quality of life. Many patients develop severe physical,
occupational, and social disabilities as a consequence of
their unceasing pain [8].
Depending on the applied definition, 9–34% of all HZ
patients develop PHN. The risk of developing PHN is also
age-dependent: the cumulative incidence of PHN is only
2% in HZ patients younger than 50 years of age, rising to
about 20% in those older than 50 years and to 35% in
those over 80 years [3,10-12]. Therefore, the number of
patients with this disorder is expected to increase in our
ageing society. Other important risk indicators for PHN
include the severity of acute pain and inflammation dur-
ing HZ.
Treatment of existing PHN has been rather disappointing.
In fact, most treatment strategies such as tricyclic antide-
pressants [13,14], topical capsaicin [15,16], gabapentin
[17], and controlled-release oxycodone [18], have dem-
onstrated limited effects [19]. Intrathecal steroid injec-
tions appeared to be effective in one study [20]. Further
evidence, however, of this invasive and potentially riskful
intervention is lacking.
Much attention has therefore been given to strategies to
prevent  PHN [21]. Meta-analyses showed that antiviral
medicines have no or limited effect on the incidence of
PHN, although the duration of the HZ-related pain may
be reduced [21,22]. One small randomised controlled
trial showed that early medical treatment with amitriptyl-
ine caused a 50% reduction in the occurrence of PHN
[23]. At present, there is no more evidence available.
Another preventive strategy proposed is epidural adminis-
tration of steroids with or without local anaesthetics.
These drugs can be administered either repeatedly by
means of an epidural catheter for a certain number of days
[24] or through a single epidural injection [25,26]. The
latter is less burdensome for the patient and can be per-
formed in an outpatient setting. Two retrospective,
though uncontrolled, studies on this single epidural injec-
tion demonstrated a cumulative incidence of 2% of PHN
when the injection was given during the acute phase of
HZ, i.e. within one week from the onset of the rash
[25,26]. This suggests that it is a promising strategy for
preventing PHN. However, referring all patients with HZ
to an anaesthesiologist for a preventive epidural injection
will increase short-term medical costs. Part of these costs
may be offset by savings due to a decrease in the costs
related to the treatment of PHN. Whether these savings
will outweigh the increased initial costs is subject of
research.
Since randomised trials on the effectiveness and the cost-
effectiveness of a single epidural injection of steroids and
local anaesthetics are lacking, the PINE (Prevention by
epidural Injection of postherpetic Neuralgia in the Eld-
erly) study was set up. This paper describes the rationale
and design of the study, preceded by a brief outline of the
current hypotheses of PHN pathophysiology and the pos-
sible modes of action of the intervention. In the discus-
sion we will elaborate on dilemmas encountered when
designing the study.
Rationale for the efficacy of epidural administration of 
local anaesthetics and steroids
HZ is caused by a localised infection with the varicella
zoster virus, which had been dormant in the sensory gan-
glia since the healing of a primary infection (chickenpox).
Reactivation of the virus and its spread to the correspond-
ing dermatome result in HZ. The concomitant inflamma-
tion of the peripheral nerve and skin damage are
supposedly responsible for the acute pain [27].
The pain, hyperalgesia, and allodynia can best be
explained by two different mechanisms: sensitisation and
deafferentation. Sensitisation: nociceptors become sensi-
tised following acute tissue injury, resulting in an ongoing
discharge and hyperexcitability (peripheral sensitisation);
prolonged nociceptor discharge enhances the response of
dorsal horn neurones to afferent stimuli and expands the
dorsal horn neurone's receptive field (central sensitisa-
tion), leading to allodynia without marked sensory loss.
Deafferentation: reactivation of the varicella zoster virus in
the dorsal root ganglion results in neural damage. In addi-
tion, the inflammatory response causes oedema. The
ensuing increased intrafascicular pressure may result in
impairment of endoneurial blood flow and, ultimately,
neural destruction [28]. Loss of afferent neurones causes
spontaneous activity in deafferented central neurones,
generating constant pain in an area of marked sensory loss
and minimal allodynia. Reactive sprouting of the spinalBMC Anesthesiology 2004, 4 http://www.biomedcentral.com/1471-2253/4/2
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terminals of Aβ-mechanoreceptors, which contact recep-
tors formerly occupied by C-fibres, leads to hyperalgesia
and allodynia [29].
Interventions to prevent PHN should address these pre-
sumed underlying pathophysiological mechanisms. The
provision of adequate analgesia in the acute phase might
interrupt the process of sensitisation. Reduction of acute
pain can be achieved by blocking the afferent transmis-
sion of the pain stimulus using local anaesthetics. Steroids
might forestall deafferentation, as they inhibit inflamma-
tion and hinder swelling-induced neural ischemia, thus
preventing persistent neural damage. The application of
local anaesthetics and steroids at the level of the sensory
ganglion, therefore, might be effective.
Methods / design
Study objectives
The aim of this trial is twofold: first, to quantify the effect
of a single epidural injection of local anaesthetics and cor-
ticosteroids during the acute phase of HZ in preventing
PHN and, second, to estimate the cost-effectiveness of this
intervention as compared to care-as-usual.
Design
The PINE study is a pragmatic, randomised, multicenter
clinical trial. Its design and timing of the investigations are
presented in Figure 1 and Table 1, respectively.
Patients
Patients who consult their general practitioner (GP) dur-
ing the acute phase of HZ are potentially eligible for the
PINE study. Inclusion predominantly depends on the
location of the HZ rash and the age of the patient. Since
Flow diagram of the PINE randomised trial Figure 1
Flow diagram of the PINE randomised trial
Patient meets eligibility criteria:
Randomization to strategy arms
Standard treatment:
• analgesics (if desired)
• antiviral medication 













Patient with herpes zoster consulting general 
practitioner
inclusion:
•a g e  >50 years
• herpes zoster below C6 
• skin lesions < 7 days
• sufficiently master of Dutch 
language
exclusion:
• severe clotting defect incl.
use of coumarine anticoag.
• bact. superinfection of skin 
above vertebra affect. derm.
• allergy to bupivacaine or 
methylprednisolone
• known serious disorder of 
immune system (e.g. AIDS)BMC Anesthesiology 2004, 4 http://www.biomedcentral.com/1471-2253/4/2
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the index treatment (see below) is performed by local
anaesthesiologists and fluoroscopy is not routinely avail-
able in all participating clinics, the PINE study is confined
to patients who present with HZ below the sixth cervical
dermatome. From this level downwards an epidural injec-
tion can be performed without fluoroscopy. The inclusion
criteria for the PINE study are: 1. age ≥ 50 years; 2. HZ
below dermatome C6; 3. skin rash < 7 days; and 4. suffi-
ciently mastery of the Dutch language. The exclusion for
the PINE study are: 1. severe clotting defect, including the
use of coumarine anticoagulants; 2. bacterial superinfec-
tion of the skin above the vertebra of the affected der-
matome; 3. allergy to bupivacaine or
methylprednisolone; and 4. a known serious disorder of
the immune system (e.g. AIDS).
A standard checklist encompassing the inclusion and
exclusion criteria of the study will be used to evaluate the
eligibility of those patients with acute-phase HZ, who
consult their GP, to participate in the study. Data (includ-
ing severity of pain) of all (in- and excluded) patients
older than 50 years of age, who consulted their GP within
the first week of the HZ rash, will be used afterwards to
determine whether the study included a selected group of
HZ patients and to address generalizibility of the results.
Interventions
Standard treatment (control group)
Patients randomised to the control group receive the cur-
rent standard treatment for patients in the acute phase of
HZ. This consists of analgesics (if desired by the patient)
and antiviral medication if the rash exists less than 72
hours [9]. The choice of the antiviral drug is left to the gen-
eral practitioner and is either aciclovir (500 mg five times
daily), famciclovir (500 mg three times daily), or valaci-
clovir (1000 mg three times daily). All three are adminis-
tered orally for seven days. No antiviral drugs are
prescribed if the patient has had the rash for more than 72
hours. All patients, irrespective of the duration of symp-
toms, may be prescribed any analgesic.
Epidural injection (index group)
Patients randomised to the epidural injection group will
receive the same treatment regimens as the control group
using the same criteria for the prescription of antiviral
medication. In addition, they will be given an epidural
injection of 80-mg slow-release methylprednisolone-ace-
tate and 10 mg bupivacaine. The injection will be carried
out by an anaesthesiologist in one of the local hospitals
within one working day after randomisation. The injec-
tion will be performed at the level of the affected der-
matome using the widely used "loss of resistance" or
"hanging drop" technique [30].
Endpoints
Primary endpoint
In accordance with the commonly used definition of PHN
[5-7], the primary endpoint is the presence of HZ-related
pain four weeks after enrolment in the trial. The occur-
rence of pain will be determined by asking patients
whether the pain related to HZ is (still) present, following
the recommendations of the Herpes Zoster Clinical Trial
Consensus Group [6].
Secondary endpoints
Secondary endpoints include presence of HZ-related pain
after 3 and 6 months, duration of pain (time to resolution
of pain), severity of pain as determined by visual analogue
scale (VAS) [31], re-interventions aiming to treat the HZ-
related pain (such as drug prescription, physiotherapy,
and anaesthesiological interventions), side effects, quality
of life as determined by SF-36 [32,33] and EuroQol
[34,35], costs, and the cost-effectiveness. Data will be col-
lected about units of resource utilisation with an explicit
Table 1: The timing of the investigations.
0 1 w2 w3 w4 w2 m3 m6 m ( + 6 m )
D i a r y  +  V A S xxxxxxxxx
CES-D x x
STAI, x
EuroQol, SF-36 x x x x x
Health & Labor x x x x
GP-record analysis xx
Side effects x
Abbreviations: 0 = enrolment; 1w, 2w, 3w, and 4w = 1, 2, 3, and 4 weeks after enrolment; 2m, 3m, and 6m = 2, 3, and 6 months after enrolment; 
(+6m) = every 6 months; VAS: Visual Analogue Scale; STAI: State-Trait Anxiety Inventory; CES-D: Center for Epidemiological Studies Depression 
scale, a screening instrument for depression in the elderly; EuroQol: five-dimensional questionnaire for assessment of the health-related quality of 
life; SF-36: short form-36 Health Survey, composed of 36 questions and standardised response choices; Health and Labor: questionnaire consisting 
of four modules, to collect data on absence from work, reduced productivity, unpaid labor production, and labor-related problems; GP-record 
analysis: report from general practitioners about re-interventions aiming to treat the HZ-related pain; Side effects: report from patients about side 
effects of treatment.BMC Anesthesiology 2004, 4 http://www.biomedcentral.com/1471-2253/4/2
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clause asking whether it can be related to the PHN. Cost-
effectiveness will be addressed in terms of the incremental
costs per additional patient year free of PHN and in terms
of incremental costs per QALY gained after one and three
years. Additional estimates will be formulated for remain-
ing life expectancy. The points of time when the secondary
endpoints will be measured are shown in Table 1.
The measurement of the study endpoints will take place
using written questionnaires. The Data Co-ordinating
Center will send the questionnaires, together with self-
addressed envelopes, to the patients. In case of a non-
response, the patient will be encouraged by phone to fill
out the questionnaire. Mailing of questionnaire and end-
point measurements will take place according to the time
schedule presented in Table 1.
Statistical power
The sample size calculation has been based on a clinically
relevant reduction in the cumulative incidence of PHN
one-month after the onset of the HZ rash. Many earlier
studies showed an incidence of PHN of 20% in standardly
treated HZ patients older than 50 years [3,11,12]. How-
ever, based on data from a pilot study [4], we used a
cumulative incidence of 12% to be expected in the control
group. This could guarantee adequate numbers of patients
to perform proper analyses. Based on a two-sided alpha
error of 0.05 and 80% power, we calculated that 250
patients are needed in each treatment arm in order to
detect a reduction in the cumulative incidence from 12%
to 5%. This means that, allowing for a 10% loss of follow-
up, at least 550 patients must participate in the study.
Data analysis
Primary endpoint
The primary data analysis will include estimation of the
relative risk with 95% confidence intervals (intention-to-
treat analysis). An additional analysis will be performed
to evaluate the preventive efficacy of the intervention with
regard to the actual treatment received. To account for the
fact that the data derive from repeated measurements, we
will use Generalised Linear Mixed Models to analyse the
difference in the incidence of PHN at later moments (2, 3,
and 6 months).
Secondary endpoints
The difference in time to pain resolution between the two
treatment groups will be evaluated using Kaplan-Meyer
analyses. Difference in severity of pain and quality of life
will be compared using difference of means with 95%
confidence intervals. Difference in re-interventions and
side effects will be compared using relative risk estimates
with 95% confidence intervals. In addition, the incremen-
tal cost-effectiveness of the treatment with epidural injec-
tion versus standard treatment will be assessed. Costs are
estimated per patient by multiplying units of resource uti-
lisation with Dutch estimates of unit costs. QALY's are
estimated per patient by interpolating the valuations at
randomisation, 1 month, 3 months, 6 months, and 1
year. Difference between both treatments is tested by Gen-
eralised Linear Mixed Models. The uncertainty surround-
ing the cost effectiveness in terms of costs per additional
patient without PHN will be addressed by probability
ellipses and acceptability curves. The uncertainty sur-
rounding the cost effectiveness in terms of costs per QALY
is addressed by multivariate sensitivity analysis using a
simple model distinguishing between patients with and
without PHN.
The following planned subgroup analyses will be per-
formed: analysis according to patients' age, analysis
according to severity of pain at study entry, and analysis
according to severity of skin rash at study entry.
No interim analysis will be performed.
Ethical aspects
This study will be conducted in accordance with the prin-
ciples of the Declaration of Helsinki and GCP guidelines.
The study protocol has been approved by the Medical Eth-
ical Committee of the University Medical Center Utrecht,
Utrecht, The Netherlands. Written informed consent will
be obtained from each participating patient.
Implementation of study results
The results of the PINE study, which is supported by the
Dutch Society of Anaesthesiology and the Dutch College
of General Practitioners, will be implemented in guide-
lines for treatment of acute HZ for both anaesthesiologists
and GPs. If the intervention appears not to be effective,
anaesthesiologists and GPs will be advised to refrain from
this rather expensive and invasive procedure. In case the
effectiveness of the intervention has been demonstrated,
guidelines will indicate which patients may profit from
the epidural injection. Finally, the cost-effectiveness of the
procedure (i.e. the cost per QALY) may determine
whether this intervention will be covered by the Health
Care Insurances. It is expected, however, that any outcome
of the PINE study will contribute to a more efficient utili-
sation of the available resources for health care.
Discussion
Some aspects of the design of the PINE study, however,
must be addressed in order to appreciate its importance
for primary care.
First, we specifically opted for a pragmatic trial instead of
a placebo-controlled trial. An epidural injection is quite
burdensome and not without risks. An epidural hae-
matoma, for example, although rare, can occur and weBMC Anesthesiology 2004, 4 http://www.biomedcentral.com/1471-2253/4/2
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feel that the risk of such severe complication makes it
unethical to perform a sham injection. Besides, the addi-
tion of local anaesthetics offers immediate pain relief,
which can not be realised by a placebo. The most impor-
tant reason for a pragmatic approach, however, is that we
aim to quantify the effect of an epidural injection as might
be expected in future practice. Hence, we chose to evaluate
the addition of the epidural injection to care-as-usual.
Consequently, the placebo effects in this trial must be
considered as part of the overall treatment effect that
would also be encountered during care-as-usual in future
HZ patients.
Second, the treatment in the control group was not stand-
ardised. Meta-analyses have shown that antiviral drugs,
when given within 72 hours after the onset of the rash,
have some effect on the duration of HZ-associated pain
[21]. Hence, all patients participating in the PINE study
who consult their GP within this time limit will be pre-
scribed antiviral medicines. Since there is no clear proof of
a difference in efficacy between the three antiviral drugs
(aciclovir, famciclovir, and valaciclovir) on the develop-
ment or duration of PHN, the choice of drug is left to the
GP. However, the prescribed antiviral drug of each patient
will be registered on the data forms. One consequence of
not standardising the treatment protocol is that GPs may
prescribe therapies in addition to the antiviral medication
more often to those patients randomised to the care-as-
usual (control) group. An additional therapy, for exam-
ple, includes amitriptyline, which has been reported to
potentially prevent the development of PHN [23]. Such
therapies could reduce the observed difference in out-
come between the two groups. Although the pre-emptive
prescription of amitriptyline is unusual in The Nether-
lands, the careful registration of all prescribed drugs in
relation to HZ will enable us to correct for the possible
effect of any additional drug.
Third, epidural administration of steroids and local anaes-
thetics can be performed either repeatedly by means of an
epidural catheter for a certain number of days [24] or
through a single epidural injection [25,26]. As the latter is
less burdensome for the patients, can be performed in an
outpatient setting, and is advocated by the Dutch Society
of Anaesthesiology, we decided to evaluate the single
rather than the multiple injection therapy.
Finally, we chose for the presence of HZ-related pain four
weeks after enrolment in the trial as the primary outcome
of the PINE study, because it is the most widely advocated
definition of PHN [5,6]. There is some controversy, how-
ever, about the definition of PHN with respect to the
severity and the duration of pain after the onset of the rash
[5-7,36-38]. Some researchers define PHN as HZ-related
pain that occurs after the rash has healed, while others
describe it as HZ-related pain one [5,6] or three months
[13] after the onset of the rash. Hence, we chose as sec-
ondary outcomes the severity of pain at one month, the
presence of HZ-related pain after three and six months
since rash onset, and the duration of pain. To minimise
bias that is inherent to a subjective endpoint in an open-
label trial, we will systematically document endpoints
using structured written questionnaires.
In summary, the PINE study is the first randomised trial to
quantify the effectiveness and cost-effectiveness of an epi-
dural injection of local anaesthetics and steroids on the
prevention of postherpetic neuralgia in elderly patients
with acute-phase herpes zoster. The results of this study
may also facilitate the selection of HZ patients who are at
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